STX-721 — Investigational Agent

EGFR Inhibitor · Phase 1 · Scorpion Therapeutics / Pfizer

Mechanism of Action

Mutant-selective, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 exon 20 insertion mutations while sparing wild-type EGFR, aiming to reduce on-target wild-type toxicity. Designed to inhibit the distinct exon 20 insertion conformations driving NSCLC.

Investigational Indications

• EGFR exon 20 insertion NSCLC
• HER2 exon 20 insertion NSCLC

Key Trials